Kenkare-Mitra Sara insider trades
Kenkare-Mitra Sara has filed 21 Form 4s with the SEC that we hold, for Alector, Inc. (ALEC) (President and Head of R&D) and Unicycive Therapeutics, Inc. (UNCY) (Director). Across all of them we count 0 purchases worth $0 and 12 sales worth $663.4K reported on Form 4. In the last 12 months: 0 purchases ($0) and 1 sale ($46.7K). The largest single trade was a sale of 10,124 shares of Alector, Inc. worth $84.2K, dated 2023-03-02. The first filing on our record is dated 2022-01-05 and the latest 2026-07-28.
Alector, Inc. (ALEC)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-03-02 | S, sale reported on Form 4 | 10,124 | $84.2K | 2023-03-03 |
| 2023-06-02 | S, sale reported on Form 4 | 4,092 | $28.2K | 2023-06-05 |
| 2023-09-05 | S, sale reported on Form 4 | 6,214 | $32.3K | 2023-09-06 |
| 2023-12-04 | S, sale reported on Form 4 | 12,519 | $69.6K | 2023-12-06 |
| 2024-03-04 | S, sale reported on Form 4 | 10,169 | $70.4K | 2024-03-05 |
| 2024-06-03 | S, sale reported on Form 4 | 13,206 | $63.4K | 2024-06-04 |
| 2024-09-03 | S, sale reported on Form 4 | 13,926 | $68.0K | 2024-09-04 |
| 2024-12-02 | S, sale reported on Form 4 | 26,500 | $66.8K | 2024-12-03 |
| 2025-03-03 | S, sale reported on Form 4 | 29,073 | $42.7K | 2025-03-05 |
| 2025-06-02 | S, sale reported on Form 4 | 23,890 | $32.0K | 2025-06-04 |
| 2025-09-02 | S, sale reported on Form 4 | 23,638 | $59.1K | 2025-09-04 |
| 2025-12-03 | S, sale reported on Form 4 | 41,687 | $46.7K | 2025-12-03 |
Unicycive Therapeutics, Inc. (UNCY)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1895592) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms